HDAC6 and melanoma: XP5, an inhibitor of HDAC6, in combination with a small-molecule PD-L1 inhibitor (NP19) synergistically enhanced anti-tumor immune responses by increasing tumor-infiltrating lymphocytes while decreasing PD-L1 expression in melanoma [92].